These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22487072)

  • 21. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.
    Koh PS; Chan AC; Cheung TT; Chok KS; Dai WC; Poon RT; Lo CM
    HPB (Oxford); 2016 Jan; 18(1):72-8. PubMed ID: 26776854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
    Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
    Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.
    Shibahara J; Hayashi A; Misumi K; Sakamoto Y; Arita J; Hasegawa K; Kokudo N; Fukayama M
    Am J Surg Pathol; 2016 May; 40(5):608-16. PubMed ID: 26735856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].
    El Khaddari S; Gaudin JL; Abidi H; Picaud G; Rode A; Souquet JC
    Gastroenterol Clin Biol; 2002; 26(8-9):728-34. PubMed ID: 12434077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.
    Cheung AH; Lam CS; Tam HS; Cheung TT; Pang R; Poon RT
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):493-498. PubMed ID: 27733318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre.
    Molinari M; Kachura JR; Dixon E; Rajan DK; Hayeems EB; Asch MR; Benjamin MS; Sherman M; Gallinger S; Burnett B; Feld R; Chen E; Greig PD; Grant DR; Knox JJ
    Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):684-92. PubMed ID: 17100154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.
    Scheuermann U; Kaths JM; Heise M; Pitton MB; Weinmann A; Hoppe-Lotichius M; Otto G
    Eur J Surg Oncol; 2013 Jun; 39(6):593-600. PubMed ID: 23611755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results.
    Aliberti C; Benea G; Tilli M; Fiorentini G
    Cardiovasc Intervent Radiol; 2008; 31(5):883-8. PubMed ID: 18478290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival.
    Biolato M; Miele L; Vero V; Racco S; Di Stasi C; Iezzi R; Zanché A; Pompili M; Rapaccini GL; La Torre G; Gasbarrini A; Grieco A
    World J Gastroenterol; 2014 Jul; 20(25):8158-65. PubMed ID: 25009388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
    Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period.
    Mihalache F; Tantau M; Diaconu B; Acalovschi M
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):285-90. PubMed ID: 20922193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.
    Zou LQ; Zhang BL; Chang Q; Zhu FP; Li YY; Wei YQ; Guan YS
    World J Gastroenterol; 2014 Dec; 20(45):17227-34. PubMed ID: 25493039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.
    Chen ZX; Jian ZW; Wu XW; Wang JC; Peng JY; Lao XM
    Cancer Med; 2019 Sep; 8(11):5097-5107. PubMed ID: 31313476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.